Detalhe da pesquisa
1.
Pharmacogenomics of bortezomib test-dosing identifies hyperexpression of proteasome genes, especially PSMD4, as novel high-risk feature in myeloma treated with Total Therapy 3.
Blood
; 118(13): 3512-24, 2011 Sep 29.
Artigo
em Inglês
| MEDLINE | ID: mdl-21628408
2.
High-risk myeloma is associated with global elevation of miRNAs and overexpression of EIF2C2/AGO2.
Proc Natl Acad Sci U S A
; 107(17): 7904-9, 2010 Apr 27.
Artigo
em Inglês
| MEDLINE | ID: mdl-20385818
3.
Superior results of Total Therapy 3 (2003-33) in gene expression profiling-defined low-risk multiple myeloma confirmed in subsequent trial 2006-66 with VRD maintenance.
Blood
; 115(21): 4168-73, 2010 May 27.
Artigo
em Inglês
| MEDLINE | ID: mdl-20124509
4.
Total Therapy 3 for multiple myeloma: prognostic implications of cumulative dosing and premature discontinuation of VTD maintenance components, bortezomib, thalidomide, and dexamethasone, relevant to all phases of therapy.
Blood
; 116(8): 1220-7, 2010 Aug 26.
Artigo
em Inglês
| MEDLINE | ID: mdl-20501894
5.
Extramedullary disease portends poor prognosis in multiple myeloma and is over-represented in high-risk disease even in the era of novel agents.
Haematologica
; 97(11): 1761-7, 2012 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-22689675
6.
Gene expression profiling of plasma cells at myeloma relapse from tandem transplantation trial Total Therapy 2 predicts subsequent survival.
Blood
; 113(26): 6572-5, 2009 Jun 25.
Artigo
em Inglês
| MEDLINE | ID: mdl-19389881
7.
Complete remission in multiple myeloma examined as time-dependent variable in terms of both onset and duration in Total Therapy protocols.
Blood
; 114(7): 1299-305, 2009 Aug 13.
Artigo
em Inglês
| MEDLINE | ID: mdl-19515721
8.
Thalidomide arm of Total Therapy 2 improves complete remission duration and survival in myeloma patients with metaphase cytogenetic abnormalities.
Blood
; 112(8): 3115-21, 2008 Oct 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-18492953
9.
Seven-year median time to progression with thalidomide for smoldering myeloma: partial response identifies subset requiring earlier salvage therapy for symptomatic disease.
Blood
; 112(8): 3122-5, 2008 Oct 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-18669874
10.
TP53 deletion is not an adverse feature in multiple myeloma treated with total therapy 3.
Br J Haematol
; 147(3): 347-51, 2009 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-19702643
11.
Targeting Akt and heat shock protein 90 produces synergistic multiple myeloma cell cytotoxicity in the bone marrow microenvironment.
Clin Cancer Res
; 14(3): 865-74, 2008 Feb 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-18245550
12.
Proteomic analysis of waldenstrom macroglobulinemia.
Cancer Res
; 67(8): 3777-84, 2007 Apr 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-17440091
13.
Editor's Note: Targeting Akt and Heat Shock Protein 90 Produces Synergistic Multiple Myeloma Cell Cytotoxicity in the Bone Marrow Microenvironment.
Clin Cancer Res
; 30(4): 922, 2024 Feb 16.
Artigo
em Inglês
| MEDLINE | ID: mdl-38362725
14.
Proteomics analysis in post-transplant lymphoproliferative disorders.
Eur J Haematol
; 81(4): 298-303, 2008 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-18573174
15.
Benefit of complete response in multiple myeloma limited to high-risk subgroup identified by gene expression profiling.
Clin Cancer Res
; 13(23): 7073-9, 2007 Dec 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-18056185
16.
Combination mammalian target of rapamycin inhibitor rapamycin and HSP90 inhibitor 17-allylamino-17-demethoxygeldanamycin has synergistic activity in multiple myeloma.
Clin Cancer Res
; 12(22): 6826-35, 2006 Nov 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-17121904
17.
Thalidomide in total therapy 2 overcomes inferior prognosis of myeloma with low expression of the glucocorticoid receptor gene NR3C1.
Clin Cancer Res
; 18(19): 5499-506, 2012 Oct 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-22855579
18.
International staging system and metaphase cytogenetic abnormalities in the era of gene expression profiling data in multiple myeloma treated with total therapy 2 and 3 protocols.
Cancer
; 117(5): 1001-9, 2011 Mar 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-20945320
19.
Complete remission sustained 3 years from treatment initiation is a powerful surrogate for extended survival in multiple myeloma.
Cancer
; 113(2): 355-9, 2008 Jul 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-18470907
20.
Cytogenetically defined myelodysplasia after melphalan-based autotransplantation for multiple myeloma linked to poor hematopoietic stem-cell mobilization: the Arkansas experience in more than 3,000 patients treated since 1989.
Blood
; 111(1): 94-100, 2008 Jan 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-17895401